Pharmaceuticals & Life Sciences

Agentic Workflow Automation for Pharmaceuticals & Life Sciences

Agentic Workflow Automation for pharmaceuticals & life sciences, built around the constraint that defines the sector: GxP validation means every system change needs documented evidence before it reaches production.

Regulations in scope
5
Systems we integrate
5
Typical first release
6 weeks

What changes when it is pharmaceuticals & life sciences

We baseline your cycle time and cost before we build anything, so the business case is measured rather than asserted. If a workflow is not worth automating, we will tell you in week one.

In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production. That single fact reshapes how agentic workflow automation has to be built here, the guardrails, the approval points and the evidence trail are design inputs rather than things bolted on before go-live.

The workload we are most often asked to take on first is literature monitoring, usually integrated against SAP. We build the smallest thing that proves the case, put it in front of real users, and expand only what earns its keep.

Deployed across regulated and unregulated sectors, with audit trails where the regulator expects them. You own the code, the models where they are open-weight, and the documentation to run it without us.

The sector constraints we design around

Defining constraint
GxP validation means every system change needs documented evidence before it reaches production
Regulations in scope
CDSCO · US FDA 21 CFR Part 11 · EU GMP Annex 11 · GxP validation · ICH guidelines
Systems of record
LIMS · QMS · eTMF · SAP · pharmacovigilance databases
Where we usually start
batch record review

Agentic Workflow Automation workloads in pharmaceuticals & life sciences

  • batch record review
  • adverse event intake and coding
  • regulatory dossier assembly
  • deviation and CAPA drafting
  • literature monitoring

What is included

  • Process mapping and automation candidacy scoring
  • Agent design per workflow stage
  • Exception handling and escalation paths
  • Approval gates with full audit trail
  • Cycle-time and cost baselines, measured before and after
  • Change management and team training

Questions from this sector

Can an AI system be GxP validated?

Yes, with a documented validation approach, IQ/OQ/PQ, defined intended use, change control and evidence of consistent performance. We build the validation pack alongside the system, not afterwards.

How do you handle 21 CFR Part 11?

Audit trails, electronic signatures, access control and record integrity designed in from the start, because retrofitting them is effectively a rebuild.

How is this different from RPA?

RPA follows fixed rules on fixed screens and breaks when either changes. Agentic automation reads context, handles variation, and escalates what it cannot resolve, so it keeps working when the process drifts.

How do you prove the ROI?

We baseline cycle time, touch count and cost per transaction before building, then measure the same figures after. The comparison is the deliverable, not a projection.

What if the agent hits a case it cannot handle?

It escalates with full context to the right human, and that exception feeds back into the next iteration. Coverage rises over time rather than being promised on day one.

Agentic Workflow Automation for pharmaceuticals & life sciences, worth a conversation?

Tell us the workload and the regulation it sits under. We will tell you what is realistic.

Or email bd@dtrasglobal.com · call +91 74118 77878